225 related articles for article (PubMed ID: 34622316)
1. Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Kuykendall AT; Sun L; Mascarenhas J; Kiladjian JJ; Vannucchi AM; Wang J; Xia Q; Zhu E; Feller F; Rizo A; Bussolari J; Wan Y; Komrokji R
Ann Hematol; 2022 Jan; 101(1):139-146. PubMed ID: 34622316
[TBL] [Abstract][Full Text] [Related]
2. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
Mascarenhas J; Harrison CN; Kiladjian JJ; Komrokji RS; Koschmieder S; Vannucchi AM; Berry T; Redding D; Sherman L; Dougherty S; Peng L; Sun L; Huang F; Wan Y; Feller FM; Rizo A; Verstovsek S
Future Oncol; 2022 Jul; 18(22):2393-2402. PubMed ID: 35510486
[TBL] [Abstract][Full Text] [Related]
3. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
Verstovsek S; Parasuraman S; Yu J; Shah A; Kumar S; Xi A; Harrison C
Ann Hematol; 2022 Jan; 101(1):131-137. PubMed ID: 34625831
[TBL] [Abstract][Full Text] [Related]
4. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
5. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
8. Practical management of patients with myelofibrosis receiving ruxolitinib.
Harrison C; Mesa R; Ross D; Mead A; Keohane C; Gotlib J; Verstovsek S
Expert Rev Hematol; 2013 Oct; 6(5):511-23. PubMed ID: 24083419
[TBL] [Abstract][Full Text] [Related]
9. Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: Case-report, literature review, and French pharmacovigilance data.
Moutel M; Noel V; Jary A; Le QH; Lier C; Viguier M; Lebbe C; Azzouz B; Bani-Sadr F
Am J Hematol; 2022 Jan; 97(1):E31-E34. PubMed ID: 34724250
[No Abstract] [Full Text] [Related]
10. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
Talpaz M; Paquette R; Afrin L; Hamburg SI; Prchal JT; Jamieson K; Terebelo HR; Ortega GL; Lyons RM; Tiu RV; Winton EF; Natrajan K; Odenike O; Claxton D; Peng W; O'Neill P; Erickson-Viitanen S; Leopold L; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
J Hematol Oncol; 2013 Oct; 6(1):81. PubMed ID: 24283202
[TBL] [Abstract][Full Text] [Related]
11. A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.
Oritani K; Okamoto S; Tauchi T; Saito S; Ohishi K; Handa H; Takenaka K; Gopalakrishna P; Amagasaki T; Ito K; Akashi K
Int J Hematol; 2015 Mar; 101(3):295-304. PubMed ID: 25638222
[TBL] [Abstract][Full Text] [Related]
12. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
13. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Cervantes F; Vannucchi AM; Kiladjian JJ; Al-Ali HK; Sirulnik A; Stalbovskaya V; McQuitty M; Hunter DS; Levy RS; Passamonti F; Barbui T; Barosi G; Harrison CN; Knoops L; Gisslinger H;
Blood; 2013 Dec; 122(25):4047-53. PubMed ID: 24174625
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib: the first agent approved for myelofibrosis.
Verstovsek S
Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352
[No Abstract] [Full Text] [Related]
15. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
Kvasnicka HM; Thiele J; Bueso-Ramos CE; Sun W; Cortes J; Kantarjian HM; Verstovsek S
J Hematol Oncol; 2018 Mar; 11(1):42. PubMed ID: 29544547
[TBL] [Abstract][Full Text] [Related]
16. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
Verstovsek S; Kiladjian JJ; Vannucchi AM; Mesa RA; Squier P; Hamer-Maansson JE; Harrison C
Cancer; 2023 Jun; 129(11):1681-1690. PubMed ID: 36840971
[TBL] [Abstract][Full Text] [Related]
17. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
[TBL] [Abstract][Full Text] [Related]
18. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
Verstovsek S; Gotlib J; Mesa RA; Vannucchi AM; Kiladjian JJ; Cervantes F; Harrison CN; Paquette R; Sun W; Naim A; Langmuir P; Dong T; Gopalakrishna P; Gupta V
J Hematol Oncol; 2017 Sep; 10(1):156. PubMed ID: 28962635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
